An FDA advisory panel voted 10 to 3 on Thursday that the key trial data behind an experimental melanoma treatment are evaluable and clinically meaningful, siding with the manufacturer over the agency's own scientific reviewers. The FDA is scheduled to decide whether to approve the product by Monday.
The Cellular, Tissue, and Gene Therapies Advisory Committee reviewed Biologics License Application 125827 from Replimune for vusolimogene oderparepvec, known as RP1, given in combination with nivolumab. The proposed use is for adults with advanced melanoma who have already progressed on a regimen containing an anti-PD-1 drug.
That population is the reason this matters. Roughly half of people with advanced melanoma either do not respond to checkpoint blockade or progress after it, according to Replimune, and the options remaining after that point are limited. For patients and families in that position, the temptation after a favorable vote is to assume something has become available. It has not.
What the Vote Did and Did Not Decide
Advisory committees give the FDA independent expert advice. Their recommendations are non-binding. The agency generally follows them but is not required to.
The committee was asked two questions: whether the single-arm IGNYTE study allows a reliable determination of response rate and durability in the proposed population, and whether the observed responses are clinically meaningful and indicative of systemic antitumor activity. The 10-to-3 vote answered in favor.
That is narrower than it sounds. The panel did not vote on safety, approval, or how the product should be used. It answered a question about whether a particular body of evidence can be interpreted. The FDA now weighs that alongside its own review.
Why FDA Reviewers Objected
The disagreement is about study design, and it is worth understanding because it shapes what patients would actually know if the product is approved.
IGNYTE is a phase 1/2 single-arm trial, meaning every participant received the combination and there was no comparison group. Agency reviewers said in briefing documents released ahead of the meeting that this design makes it difficult to determine whether tumor shrinkage was driven by RP1 or by the nivolumab it was paired with. Reviewers also characterized a survival analysis the company presented as not interpretable. Replimune shares fell roughly 30 percent after the documents were posted.
The FDA had advised the company to run a randomized trial using nivolumab alone as the control arm. Replimune maintained that such a design lacked equipoise, meaning it considered it ethically difficult to assign patients to a treatment already known to be failing them.
The company points to a 33.6 percent objective response rate in IGNYTE and argues this is roughly five times the 5 to 7 percent response rate expected from continued anti-PD-1 therapy after definitive progression. That comparison comes from the manufacturer and is drawn across different studies rather than from a head-to-head trial, which is precisely the limitation the FDA reviewers raised. Replimune also cites the 2024 accelerated approval of lifileucel, granted on a single-arm trial of 73 patients with a 31.5 percent response rate in a similar population, as precedent.
A randomized confirmatory trial, IGNYTE-3, is underway. Overall survival data from it are not expected until 2030.
What Patients and Families Should Do Between Now and Monday
Nothing about this vote changes anyone's treatment plan today, and no one should defer a decision about currently available therapy while waiting for an announcement.
If you or a family member has advanced melanoma that has progressed after immunotherapy, the productive conversation to have with an oncologist is about the full set of options available now. Those may include clinical trial enrollment, tumor-infiltrating lymphocyte therapy, targeted therapy if the tumor carries a matching mutation, or other combinations. An oncologist can also say whether a patient would plausibly fit the proposed RP1 population if approval comes.
Trial enrollment is worth asking about specifically. IGNYTE-3 and other melanoma studies are actively recruiting at cancer centers, and eligibility is often narrower and more time-sensitive than patients expect. Waiting for a possible approval can close a trial window that was open.
If the FDA does approve the product by Monday, availability would still not be immediate. Manufacturing, distribution, site training for an intratumoral therapy, and insurance coverage determinations all follow approval rather than accompany it. Coverage for a newly approved oncology biologic frequently requires prior authorization, and patients should expect their oncology practice to handle that process rather than assume the drug can be scheduled the following week.
What Remains Unresolved
Several things are genuinely unknown, and a favorable advisory vote does not settle them.
Whether the combination extends survival has not been demonstrated. Response rate measures tumor shrinkage, not how long people live, and the trial designed to answer the survival question will not report for years. Whether the benefit seen in IGNYTE is attributable to RP1 specifically, rather than to nivolumab, remains the central scientific dispute and was not resolved by the vote.
It is also unknown whether the FDA will follow the committee. The agency has now issued two complete response letters on this application, the first in July 2025 and the second in April 2026, and its reviewers raised concerns again this week. A third rejection remains possible. So does approval, including accelerated approval conditioned on the confirmatory trial.
The FDA decision goal date is August 2, 2026. Replimune has said it expects to announce the outcome. MedicalDaily will report the agency's decision and, if approval is granted, what the labeled population and access pathway actually look like for patients.
Frequently Asked Questions
Does this vote mean the treatment is approved? No. Advisory committee recommendations are non-binding advice to the FDA. The agency has a decision goal date of August 2, 2026, and could approve, reject, or delay.
Who would this treatment be for? The proposed indication is adults with advanced melanoma who have already progressed on a regimen containing an anti-PD-1 drug. It is not proposed for newly diagnosed or early-stage melanoma.
What did the FDA's own reviewers object to? Reviewers said the single-arm trial design makes it hard to separate the effect of RP1 from the nivolumab given alongside it, and described a survival analysis the company presented as not interpretable.
Has the treatment been rejected before? Yes. The FDA issued complete response letters in July 2025 and April 2026. This is the third application, resubmitted in May 2026 and accepted for review in June.
Does the trial show people live longer? Not established. IGNYTE measured tumor response, not survival. The randomized confirmatory trial, IGNYTE-3, is not expected to report overall survival data until 2030.
If it is approved, how soon could patients get it? Not immediately. Manufacturing, distribution, treatment site readiness, and insurance authorization all follow approval. Patients should expect a lag and should ask their oncology practice about the coverage process.
What should patients do right now? Talk with an oncologist about all currently available options, including clinical trials, rather than waiting on a regulatory announcement. Do not delay or change existing treatment based on a news report.
